Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2019 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
March 05, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
March 04, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
February 27, 2019 16:35 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
February 22, 2019 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
February 21, 2019 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
February 16, 2019 06:00 ET | Source: Calithera Biosciences, Inc.

Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
February 04, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
January 07, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
November 30, 2018 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...